Innovation in oncology with CD19 CAR-T cell immunotherapy for the treatment of acute lymphoblastic leukemia: an integrative review
DOI:
https://doi.org/10.11606/issn.1679-9836.v104i4e-230155Keywords:
Acute Lymphoblastic Leukemia, Therapeutic Innovation, CAR-T Cells, ImmunotherapyAbstract
Introduction: Acute Lymphoblastic Leukemia is a neoplasm whose conventional therapeutic approach includes chemotherapy and hematopoietic cell transplantation. However, immunotherapeutic innovations with CAR-T cells, genetically modified to express chimeric antigens capable of identifying specific blast cell antigens, especially targeting the CD19 antigen, have been shown to induce significant remissions. The study provides an analysis of the efficacy and impact of CD19 CAR-T cells on the survival of patients with relapsed or refractory ALL, with the aim of highlighting this promising innovation in oncology. Objective: To summarize the main oncological innovations with CD19 CAR-T cell immunotherapy in the treatment of patients with ALL. Methods: Integrative literature review with articles published in indexed databases: PubMED, SciELO and VHL. Results: The final sample consisted of 10 articles that showed promising results, with high remission rates, with overall and event-free survival. Although the appearance of cytokine release syndrome was reported as the most frequent complication. Conclusion: The scientific evidence has shown that this therapeutic innovation in oncology using immune modulation is promising for patients undergoing treatment for relapsed and refractory ALL.
Downloads
References
Mancero-Rodríguez MJ, Arellano-Salinas KP, Santo-Cepeda KA, Rodríguez-Revelo ME. Leucemia linfoblástica aguda diagnóstico. RECIMUNDO: Rev Cient Invest Conoc. 2020 4(2):53-63. https://dialnet.uni rioja.es/descarga/articulo/7591561.pdf. Doi: https://doi.org/10.26820/recimundo/4.(2).mayo.2020.53-63
Almeida SA de, Melo ALM, Carvalho LS, Constante MM, Assunção MAA. Imunoterapia com células CAR-T como nova perspectiva de tratamento da leucemia linfoblástica aguda recidivada/refratária. Rev Méd Minas Gerais. 2021. https://www.rmmg.org/artigo/detalhes/3839 Doi: https://dx.doi.org/10.5935/2238-3182.20210052
Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933289/ Doi: https://doi.org/10.1182/blood.2019001641
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://ehoonline.biomedcentral.com/articles/10.1186/2162-3619-1-36 Doi: https://doi.org/10.1186/2162-36-19-1-36
Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, et al.: CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2020;35(1):75-89. https://doi.org/10.1038/s41375-020-0792-2 Doi: https://www.nature.com/articles/s41375-020-0792-2
MSD Manuals. Leucemia linfoblástica aguda (LLA). Versão para profissionais [Internet]. 2023. https://www.msdmanuals.com/pt/profissional/hematologia-e-oncologia/leucemia/leucemia-linfobl%C3%A1stica-aguda-lla#Diagn%C3%B3stico_v41356865_pt
Sawada NO, Nicolussi AC, Paula JM de, Garcia-Caro MP, Marti-Garcia C, Cruz-Quintana F. Quality of life of Brazilian and Spanish cancer patients undergoing chemotherapy: an integrative literature review. Rev Latino-Americana Enf. 2016;24(0). https://www.scielo.br/j/rlae/a/CD8Sq6TyvLnnGjWNY7XvQHf/?format=pdf&lang=pt Doi: https://doi.org/10.1590/1518-8345.0564.2688
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. Rev Panam Salud Pública. 2022;46:1. https://iris.paho.org/bitstream/handle/10665.2/56882/v46e1122022.pdf?sequence=5 Doi: https://doi.org/10.26633/RPSP.2022.112
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NEJM. 2014;371(16):1507-17. https://www.nejm.org/doi/full/10.1056/NEJMoa1407222 Doi: https://doi.org/10.1056/NEJMoa1407222
Shiqi L, Jiasi Z, Lvzhe C, Huailong X, Liping H, Lin L, et al. Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T. Mol Ther Oncol. 2023. https://pubmed.ncbi.nlm.nih.gov/37215385/ Doi: https://doi.org/10.1016/j.omto.2023.04.003
Zhang X, Lu X, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325-38. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252549/ Doi: https://doi.org/10.1182/bloodadvances.2020001466
Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, et al. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):122. https://pubmed.ncbi.nlm.nih.gov/32894185/ Doi: https://doi.org/10.1186/s13045-020-00953-8
Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, et al. Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL. Clin Cancer Res. 2023;29(4):742-53. https://pubmed.ncbi.nlm.nih.gov/36255386/ Doi: https://doi.org/10.1158/1078-0432
An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q, et al. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nature Commun. 2020;11. https://www.nature.com/articles/s41467-020-19774-x Doi: https://doi.org/10.1038/s41467-020-19774-x
Wang S, Wang X, Ye C, Cheng H, Shi M, Chen W, et al. Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia. Am J Hematol. 2021;96(5):E162-E165. https://pubmed.ncbi.nlm.nih.gov/33580974/ Doi: https://doi.org/10.1002/ajh.26123
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. NEJM. 2018;378(5):449-59. https://pubmed.ncbi.nlm.nih.gov/29385376/ Doi: https://doi.org/10.1056/NEJMoa1709919
Heng G, Jia J, Li S, Fu G, Wang M, Qin D, et al. Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2020;26(7):1606-15. https://pubmed.ncbi.nlm.nih.gov/31732519/ Doi: https://doi.org/10.1158/1078-0432.CCR-19-1339
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. NEJM. 2018;378(5):439-48. https://www.nejm.org/doi/full/10.1056/NEJMoa1709866 Doi: https://doi.org/10.1056/NEJMoa1709866
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Vitória Vitoriano da Costa, Laura Valcante , Maria Luiza Garcia Ferreira, Rebeca Ribeiro, Giovana Alves Diniz, Eliza Tran, Sabrina Thalita dos Reis
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
